Big pharma Phase III setbacks

Two pharmaceutical companies, Roche and Pharmacia (PHA), announced that they halted development of compounds following unfavorable Phase III data. Roche said it has discontinued late-stage clinical development of two matrix metalloproteinase inhibitors (MMPIs) after interim

Read the full 355 word article

How to gain access

Continue reading with a
two-week free trial.